 |
|
Urine Telomerase and Bladder Cancer Detection—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In Reply: The studies noted by Dr Liu were duly cited in our pilot study.1 The results were not discussed further in the present article, which can be considered as a "phase II diagnostic study"2 of the diagnostic relevance of telomerase activity with 2 important aims, one technical and the other clinical.
In view of previous large interstudy variability of sensitivity and specificity, our technical objective was to optimize the reproducibility of our results. We attempted to do this by overcoming inhibitor problems and avoiding telomerase enzyme degradation through the standardization of the preanalytical phase (sample amount and storage conditions), and by setting up and using a fluorescent quantitative assay with an internal standard. This not only permits a better quantification of telomerase activity, but also avoids the risk of false negative results. Our study represents a verification of the 50 AEU cutoff value to maximally discriminate between healthy individuals . . . [Full Text of this Article]
Maria Aurora Sanchini, MSc
Division of Oncology and Diagnostics
Morgagni-Pierantoni Hospital
Oriana Nanni, MSc
Istituto Oncologico Romagnolo
Daniele Calistri, PhD
biomolec@ausl.fo.it
Division of Oncology and Diagnostics
Morgagni-Pierantoni Hospital
Forlì, Italy
RELATED ARTICLES
Urine Telomerase and Bladder Cancer Detection
Brian C.-S. Liu
JAMA. 2006;295(9):998.
EXTRACT
| FULL TEXT
Urine Telomerase and Bladder Cancer Detection
Steffen Weikert, Frank Christoph, and Kurt Miller
JAMA. 2006;295(9):998-999.
EXTRACT
| FULL TEXT
Relevance of Urine Telomerase in the Diagnosis of Bladder Cancer
Maria Aurora Sanchini, Roberta Gunelli, Oriana Nanni, Sara Bravaccini, Carla Fabbri, Alice Sermasi, Eduard Bercovich, Alberto Ravaioli, Dino Amadori, and Daniele Calistri
JAMA. 2005;294(16):2052-2056.
ABSTRACT
| FULL TEXT
|
